Savara

Historical price data

Savara is a clinical-stage biopharmaceutical company with a mission to develop and commercialize novel therapies for rare respiratory diseases, starting with autoimmune pulmonary alveolar proteinosis (aPAP). Its core achievement is the advancement of its lead candidate, molgramostim, into Phase 3 development with a validated Marketing Authorization Application (MAA) under review by the European Medicines Agency. The company's strategy centers on targeted pulmonary delivery of GM-CSF to correct a fundamental disease mechanism, aiming to secure regulatory approvals and establish a commercial footprint in the global orphan drug market. Savara's experienced leadership team, with proven track records in rare disease commercialization, is executing this focused plan to transition into a commercial-stage entity.

Proprietary nebulizer system for the localized inhaled delivery of granulocyte-macrophage colony-stimulating factor (GM-CSF) directly to the lungs, designed to treat diseases characterized by alveolar macrophage dysfunction.

Molgramostim's primary competition is the invasive procedural standard of care, whole lung lavage, as there are no approved pharmacologic therapies for aPAP. Savara holds a substantial first-mover advantage with late-stage data and a regulatory submission, creating a high barrier for potential future drug entrants. The key competitive battle will be in market education and shifting treatment paradigms rather than direct drug-to-drug competition in the near term.